AWT020

Phase 1Small molecule

AAnwita Biosciences

AWT020 is one of 100 small molecule programs targeting Advanced Cancers. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced CancersRecruiting

Solid TumorRecruiting

Advanced CancerRecruiting

Advanced CancersPhase 1

Recruiting

Solid TumorPhase 1

Recruiting

Advanced CancerPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

Fludara

Sanofi

Preclinical

1 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Tulmimetostat

Novartis

Preclinical

1 8

Soc

Pfizer

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

AWT020

AAnwita Biosciences

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Advanced Cancer

NCT06092580

Q2 2028

Phase 1Recruiting

Solid Tumor

NCT06839105

Q1 2029

Phase 1Recruiting

Advanced Cancers

NCT07822919

Clinical

Trials by Indication[1]

Advanced Cancer1 trial

Phase 1 Study of AWT020 in Advanced Cancer

Recruiting·AAnwita Biosciences·Phase 1·NCT06092580·60 enrolled

Advanced Cancers1 trial

A Phase 1 Study of AWT020 in Patients With Advanced Solid Tumors

Recruiting·AAnwita Biosciences·Phase 1·NCT07822919·96 enrolled

Solid Tumor1 trial

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AWT020 Alone and in Combination With Other Antitumor Therapies in Patients With Advanced Malignancies

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06839105·214 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AWT020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AWT020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AWT020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anwita Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAnwita Biosciences

AWT020

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2028

Q1 2029

Trials by Indication[1]

Advanced Cancer1 trial

Advanced Cancers1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News